WEKO3
アイテム
{"_buckets": {"deposit": "c0a7d71b-7910-43fc-834d-f4aaa8c4bafc"}, "_deposit": {"created_by": 15, "id": "13890", "owners": [15], "pid": {"revision_id": 0, "type": "depid", "value": "13890"}, "status": "published"}, "_oai": {"id": "oai:mie-u.repo.nii.ac.jp:00013890", "sets": ["1692684776404"]}, "author_link": ["45503", "45504"], "item_8_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2019-05-27", "bibliographicIssueDateType": "Issued"}}]}, "item_8_description_14": {"attribute_name": "フォーマット", "attribute_value_mlt": [{"subitem_description": "application/pdf", "subitem_description_type": "Other"}]}, "item_8_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "本研究では、ICIの作用部位であるエフェクターT細胞、NK細胞の特性変化について、末梢血を試料として治療効果や副作用との関連性を評価した。ROC解析より、好中球数およびCD28陽性CD8陽性T細胞数は、non-PDの予測率がそれぞれ81.8%、72.7%であった。ICI治療早期における好中球数やCD28陽性CD8陽性T細胞は、ICI治療を予測するバイオマーカーとなる可能性がある。", "subitem_description_type": "Abstract"}, {"subitem_description": "This study was performed to investigate the association of host factors including peripheral blood cell characteristics with the PD-1/PD-L1 therapy. A total of 20 patients were enrolled. The number of patients administrated pembrolizumab, nivolumab, and atezolizumab was 12, 7 and 1, respectively. Twelve patients were diagnosed as progressive disease (PD), and 8 were non-PD. All 6 female patients were diagnosed as PD. In the blood sample obtained within 3 weeks from the immune therapy, significantly high CD28 positive CD8+ T lymphocyte counts and low neutrophil counts were observed in the non-PD patients compared with the PD patients. Meanwhile, the distribution of tumor PD-L1 levels, clinical stage of NSCLC, and other immune markers investigated in the non-PD patients were comparable with the PD patients. CD28 positive CD8+ T lymphocyte and neutrophil counts were considered to be possible biomarkers related to the efficacy of PD-1/PD-L1 therapy.", "subitem_description_type": "Abstract"}]}, "item_8_description_5": {"attribute_name": "内容記述", "attribute_value_mlt": [{"subitem_description": "2016年度~2018年度科学研究費補助金(基盤研究(C))研究成果報告書", "subitem_description_type": "Other"}]}, "item_8_description_64": {"attribute_name": "科研費番号", "attribute_value_mlt": [{"subitem_description": "16K08369", "subitem_description_type": "Other"}]}, "item_8_publisher_30": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "三重大学"}]}, "item_8_text_31": {"attribute_name": "出版者(ヨミ)", "attribute_value_mlt": [{"subitem_text_value": "ミエダイガク"}]}, "item_8_text_65": {"attribute_name": "資源タイプ(三重大)", "attribute_value_mlt": [{"subitem_text_value": "Kaken / 科研費報告書"}]}, "item_8_version_type_15": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_970fb48d4fbd8a85", "subitem_version_type": "VoR"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "岩本, 卓也", "creatorNameLang": "ja"}, {"creatorName": "イワモト, タクヤ", "creatorNameLang": "ja-Kana"}, {"creatorName": "Iwamoto, Takuya", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "45503", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "奥田, 真弘", "creatorNameLang": "ja"}, {"creatorName": "オクダ, マサヒロ", "creatorNameLang": "ja-Kana"}, {"creatorName": "OKUDA, masahiro", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "45504", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2020-11-16"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "2020RP0048.pdf", "filesize": [{"value": "250.6 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_note", "mimetype": "application/pdf", "size": 250600.0, "url": {"label": "2020RP0048", "url": "https://mie-u.repo.nii.ac.jp/record/13890/files/2020RP0048.pdf"}, "version_id": "9cbd959f-547f-43e8-affe-aa6edf98b3f3"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "免疫チェックポイント阻害薬", "subitem_subject_scheme": "Other"}, {"subitem_subject": "バイオマーカー", "subitem_subject_scheme": "Other"}, {"subitem_subject": "がん化学療法", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "jpn"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "research report", "resourceuri": "http://purl.org/coar/resource_type/c_18ws"}]}, "item_title": "免疫チェックポイント阻害薬のPK/PD評価系構築と個別化治療への応用", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "免疫チェックポイント阻害薬のPK/PD評価系構築と個別化治療への応用", "subitem_title_language": "ja"}, {"subitem_title": "Construction of PK/PD evaluation system for optimizing treatment using immune checkpoint inhibitors", "subitem_title_language": "en"}]}, "item_type_id": "8", "owner": "15", "path": ["1692684776404"], "permalink_uri": "http://hdl.handle.net/10076/00019508", "pubdate": {"attribute_name": "PubDate", "attribute_value": "2020-11-16"}, "publish_date": "2020-11-16", "publish_status": "0", "recid": "13890", "relation": {}, "relation_version_is_last": true, "title": ["免疫チェックポイント阻害薬のPK/PD評価系構築と個別化治療への応用"], "weko_shared_id": -1}
免疫チェックポイント阻害薬のPK/PD評価系構築と個別化治療への応用
http://hdl.handle.net/10076/00019508
http://hdl.handle.net/10076/00019508c5807bb0-3a28-41f5-8996-b92c9e8695bc
名前 / ファイル | ライセンス | アクション |
---|---|---|
2020RP0048 (250.6 kB)
|
|
Item type | 報告書 / Research Paper(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2020-11-16 | |||||
タイトル | ||||||
言語 | ja | |||||
タイトル | 免疫チェックポイント阻害薬のPK/PD評価系構築と個別化治療への応用 | |||||
タイトル | ||||||
言語 | en | |||||
タイトル | Construction of PK/PD evaluation system for optimizing treatment using immune checkpoint inhibitors | |||||
言語 | ||||||
言語 | jpn | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | 免疫チェックポイント阻害薬 | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | バイオマーカー | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | がん化学療法 | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_18ws | |||||
資源タイプ | research report | |||||
著者 |
岩本, 卓也
× 岩本, 卓也× 奥田, 真弘 |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | 本研究では、ICIの作用部位であるエフェクターT細胞、NK細胞の特性変化について、末梢血を試料として治療効果や副作用との関連性を評価した。ROC解析より、好中球数およびCD28陽性CD8陽性T細胞数は、non-PDの予測率がそれぞれ81.8%、72.7%であった。ICI治療早期における好中球数やCD28陽性CD8陽性T細胞は、ICI治療を予測するバイオマーカーとなる可能性がある。 | |||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | This study was performed to investigate the association of host factors including peripheral blood cell characteristics with the PD-1/PD-L1 therapy. A total of 20 patients were enrolled. The number of patients administrated pembrolizumab, nivolumab, and atezolizumab was 12, 7 and 1, respectively. Twelve patients were diagnosed as progressive disease (PD), and 8 were non-PD. All 6 female patients were diagnosed as PD. In the blood sample obtained within 3 weeks from the immune therapy, significantly high CD28 positive CD8+ T lymphocyte counts and low neutrophil counts were observed in the non-PD patients compared with the PD patients. Meanwhile, the distribution of tumor PD-L1 levels, clinical stage of NSCLC, and other immune markers investigated in the non-PD patients were comparable with the PD patients. CD28 positive CD8+ T lymphocyte and neutrophil counts were considered to be possible biomarkers related to the efficacy of PD-1/PD-L1 therapy. | |||||
内容記述 | ||||||
内容記述タイプ | Other | |||||
内容記述 | 2016年度~2018年度科学研究費補助金(基盤研究(C))研究成果報告書 | |||||
書誌情報 |
発行日 2019-05-27 |
|||||
フォーマット | ||||||
内容記述タイプ | Other | |||||
内容記述 | application/pdf | |||||
著者版フラグ | ||||||
出版タイプ | VoR | |||||
出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||
出版者 | ||||||
出版者 | 三重大学 | |||||
出版者(ヨミ) | ||||||
ミエダイガク | ||||||
科研費番号 | ||||||
内容記述タイプ | Other | |||||
内容記述 | 16K08369 | |||||
資源タイプ(三重大) | ||||||
Kaken / 科研費報告書 |